A search for alternative biomarkers suggested that T-cell differentiation, as measured by expression on CD8+ T cells of CCR7, a chemokine receptor for CCL19 and CCL21, discriminated cancer patients from normal controls (Czystowska et al., 2012). The gene discussed is CD8A; the disease is cancer.